Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0HGQF5
Tue, 26.07.2022
MagForce AG
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Application for the Opening of Insolvency Proceedings
Berlin, July 26, 2022 – Today, the Management Board of MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), in consultation with the Supervisory Board, decided, to file an app [ … ]
Tue, 26.07.2022
MagForce AG
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: Application for the Opening of Insolvency Proceedings
Berlin, July 26, 2022 – Today, the Management Board of MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), in consultation with the Supervisory Board, decided, to file an app [ … ]
Wed, 13.07.2022
MagForce AG
- Stage 2b of the trial for approval in the USA is currently ongoing
- Billing code by the American Medical Association is available
- Break-even expected from 2024
In the past financial year 2021, MagForce AG continued or resumed the
planned European roll-out for the treatment of malignant brain tumours
(glioblastoma). The four NanoActivator de [ … ]
Wed, 13.07.2022
MagForce AG
- Stage 2b of the trial for approval in the USA is currently ongoing
- Billing code by the American Medical Association is available
- Break-even expected from 2024
In the past financial year 2021, MagForce AG continued or resumed the
planned European roll-out for the treatment of malignant brain tumours
(glioblastoma). The four NanoActivator de [ … ]
Thu, 30.06.2022
MagForce AG
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce USA received approval by the Centers for Medicare and Medicaid Services (CMS) to cover the majority of treatment-related costs in the ongoing clinical trial in the US after commercial payment code approval from the American Medical Association (AM [ … ]
Thu, 30.06.2022
MagForce AG
MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
MagForce USA received approval by the Centers for Medicare and Medicaid Services (CMS) to cover the majority of treatment-related costs in the ongoing clinical trial in the US after commercial payment code approval from the American Medical Association (AM [ … ]
Sat, 25.06.2022
MagForce AG
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG issues Bearer Notes with a total Volume of up to EUR 3.5 Million to Lansdowne Investment Company Cyprus Limited
Berlin, June 25, 2022 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the [ … ]
Sat, 25.06.2022
MagForce AG
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG issues Bearer Notes with a total Volume of up to EUR 3.5 Million to Lansdowne Investment Company Cyprus Limited
Berlin, June 25, 2022 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the [ … ]
Fri, 08.04.2022
MagForce AG
MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Category III CPT codes will ensure seamless billing and tracking process for payers already at the time FDA marketing approval is secured
NanoTherm Therapy CPT codes will [ … ]
Fri, 25.02.2022
MagForce AG
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG extends EUR 5.0 million Convertible Notes agreement with Lansdowne Investment Company Cyprus Limited and issues additional Convertible Notes in the amount of EUR 2.0 million
Berlin, February 25, 2022 - MagForce AG (Frankfurt, Scale, Xetra: M [ … ]